Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I placebo-controlled single-blind study of ABO21009 in healthy volunteers and patients with rheumatoid arthritis
NL-OMON58832Phase 1Recruiting
- Sponsor
- AbolerIS Pharma
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-blind trial of ABO21009 in rheumatoid arthritis (RA) (2 arms), sponsored by AbolerIS Pharma. Started Jan 2025; status: recruiting.
02
Drugs
ABO21009
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON58832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58832.